These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 3791243

  • 1. Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation.
    Kikuchi Y, Kizawa I, Oomori K, Miyauchi M, Kita T, Sugita M, Tenjin Y, Kato K.
    Cancer Res; 1987 Jan 15; 47(2):592-6. PubMed ID: 3791243
    [Abstract] [Full Text] [Related]

  • 2. Characterization of an established cell line from human immature teratoma of the ovary and effects of retinoic acid on cell proliferation.
    Kikuchi Y, Momose E, Kizawa I, Ishida M, Sunaga H, Mukai K, Seki K, Kato K.
    Cancer Res; 1984 Jul 15; 44(7):2952-8. PubMed ID: 6202402
    [Abstract] [Full Text] [Related]

  • 3. [Therapeutic values of prostaglandin D2 in nude mice bearing human ovarian carcinoma].
    Kikuchi Y, Miyauchi M, Nagata I.
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Feb 15; 42(2):121-8. PubMed ID: 2313142
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of human ovarian cancer cell growth in vitro and in nude mice by prostaglandin D2.
    Kikuchi Y, Miyauchi M, Oomori K, Kita T, Kizawa I, Kato K.
    Cancer Res; 1986 Jul 15; 46(7):3364-6. PubMed ID: 3458525
    [Abstract] [Full Text] [Related]

  • 5. [In vitro and in vivo effects of ginsenoside Rh2 on the proliferation of serous cystadenocarcinoma of the human ovary].
    Tode T, Kikuchi Y, Sasa H, Hirata J, Kita T, Imaizumi E, Nagata I.
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 May 15; 44(5):589-94. PubMed ID: 1619319
    [Abstract] [Full Text] [Related]

  • 6. Effect of antifibrinolysis treatment on human cancer in nude mice.
    Ogawa H, Sekiguchi F, Tanaka N, Ono K, Tanaka K, Kinjo M, Iwakawa A, Naito S.
    Anticancer Res; 1982 May 15; 2(6):339-44. PubMed ID: 7168552
    [Abstract] [Full Text] [Related]

  • 7. An in vivo mouse reporter gene (human secreted alkaline phosphatase) model to monitor ovarian tumor growth and response to therapeutics.
    Nilsson EE, Westfall SD, McDonald C, Lison T, Sadler-Riggleman I, Skinner MK.
    Cancer Chemother Pharmacol; 2002 Feb 15; 49(2):93-100. PubMed ID: 11862422
    [Abstract] [Full Text] [Related]

  • 8. [Effects of lymphokine-activated killer cells and interleukin-2 on the ascites formation and the survival time of nude mice bearing human ovarian cancer cells].
    Kikuchi Y, Oomori K, Miyauchi M, Kita T, Kuki E, Iwano I, Hirata J, Nagata I.
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec 15; 41(12):1891-5. PubMed ID: 2592812
    [Abstract] [Full Text] [Related]

  • 9. Establishment and characterization of three new cell lines derived from the ascites of human ovarian carcinomas.
    Alama A, Barbieri F, Favre A, Cagnoli M, Noviello E, Pedullà F, Viale M, Foglia G, Ragni N.
    Gynecol Oncol; 1996 Jul 15; 62(1):82-8. PubMed ID: 8690298
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Inhibitory effects of oral administration of ginsenoside Rh2 on tumor growth in nude mice bearing serous cyst adenocarcinoma of the human ovary].
    Tode T, Kikuchi Y, Hirata J, Kita T, Imaizumi E, Nagata I.
    Nihon Sanka Fujinka Gakkai Zasshi; 1993 Nov 15; 45(11):1275-82. PubMed ID: 8258727
    [Abstract] [Full Text] [Related]

  • 13. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
    Pourgholami MH, Yan Cai Z, Lu Y, Wang L, Morris DL.
    Clin Cancer Res; 2006 Mar 15; 12(6):1928-35. PubMed ID: 16551879
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo.
    Yukita A, Asano M, Okamoto T, Mizutani S, Suzuki H.
    Anticancer Res; 2000 Mar 15; 20(1A):155-60. PubMed ID: 10769648
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
    Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI, Donahoe PK.
    Clin Cancer Res; 1999 Nov 15; 5(11):3488-99. PubMed ID: 10589763
    [Abstract] [Full Text] [Related]

  • 20. A newly established cel line derived from human ovarian adenocarcinoma.
    Sekiguchi M, Sakakibara K, Suzuki T, Motoyama T, Fujii G.
    Jpn J Exp Med; 1980 Aug 15; 50(4):283-92. PubMed ID: 7441907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.